NCT06947746尚未招募不适用
A Single-arm Clinical Study Assessing the Safety, Tolerability, and Preliminary Efficacy of a Single Intra-Articular Injection of hiSCs for Rheumatoid Arthritis Treatment
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- TEAEs and SAEs
研究概览
简要总结
This trial is a single-center, single-arm exploratory clinical study aimed at assessing the safety, tolerability, and preliminary efficacy of a single intra-articular injection of hiSCs for the treatment of rheumatoid arthritis.
详细描述
This trial is a single-center, single-arm exploratory clinical study aimed at assessing the safety, tolerability, and preliminary efficacy of a single intra-articular injection of hiSCs for the treatment of rheumatoid arthritis.
In this trial, participants who have given informed consent will be screened to determine their eligibility according to the inclusion and exclusion criteria. The study intervention consists of a single injection of hiSCs, and the primary endpoint will be assessed during the 24-week follow-up visit after the cell injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria
- •Voluntarily sign the informed consent;
- •Male or female aged 18-65 years (inclusive) at the time of signing the informed consent;
- •Diagnosis of RA for ≥3 months according to the ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria at the screening visit;
- •At the screening visit, presence of recurrent swelling and pain in at least one knee, with a WOMAC pain score ≥4, synovial inflammation confirmed by joint ultrasound, and no significant improvement following 3 months of anti-RA treatment (including prior use of MTX standard therapy, biologics, or small molecule targeted drugs);
- •Subjects must have received csDMARD therapy for ≥3 months, with a stable dose for ≥4 weeks prior to screening;
- •Background treatment with stable-dose MTX standard therapy, biologics, or small molecule targeted drugs, either alone or in combination, is permitted;
- •The following csDMARDs, either alone or in combination, are permitted as background treatment, provided the dose has been stable for ≥4 weeks prior to screening: oral or IV MTX (10-25 mg/week; for subjects intolerant to doses ≥10 mg/week, the dose should be ≥7.5 mg/week), SAS (≤3 g/day), hydroxychloroquine (≤400 mg/day), and LEF (≤20 mg/day);
- •Stable-dose NSAIDs are permitted, provided the dose has remained stable for ≥2 weeks prior to screening;
- •CRP or hsCRP levels exceeding the upper limit of normal at the screening visit;
- •All females of childbearing potential must have a negative blood pregnancy test within 7 days prior to treatment initiation and must not be breastfeeding. Females not of childbearing potential may be exempt from the pregnancy test and contraception if they meet one of the following criteria: age ≥50 years,not receiving hormone therapy, and at least 12 months of amenorrhea, or documented surgical sterilization. All enrolled patients (regardless of gender) must use at least one highly effective method of contraception, including adequate barrier methods, throughout the study duration;
- •Subjects must be in good overall health, able to ambulate independently (excluding those requiring a wheelchair, walker, or crutches);
- •Willingness and ability to adhere to scheduled visits, treatment regimens, laboratory tests, and other study-related procedures.
排除标准
- •Subjects who meet any of the following exclusion criteria will be excluded from this study：
- •Presence of other immune-mediated disorders at the baseline visit that may interfere with the administration or efficacy evaluation of the study intervention;
- •History or current evidence of clinically significant cardiovascular, neuropsychiatric, renal, hepatic, immune, or endocrine disorders (including uncontrolled diabetes or thyroid disease), abnormal laboratory findings, or conditions requiring medications prohibited by the study protocol. "Clinically significant" refers to conditions that, in the investigator's judgment, may jeopardize subject safety or impact efficacy or safety analyses if the disease/condition exacerbates during the study;
- •Subjects with positive test results for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis (refer to laboratory tests for details);
- •Evidence of active tuberculosis (TB) or a history of active TB without adequate documented treatment;
- •Any other acute or chronic disorder leading to coagulation dysfunction that, in the investigator's judgment, may compromise patient safety and/or interfere with the evaluation of target knee outcomes;
- •Clinically significant infection within 1 month prior to the screening visit (requiring hospitalization and parenteral administration of antibiotics, antivirals, antifungals, etc., for ≥3 days) or active infection being treated during the screening period;
- •Infection in the target knee within 3 months before baseline;
- •Intra-articular corticosteroid or other drug injections in the target knee within 3 months before baseline;
- •History of knee injury or prior knee surgery in the target knee within 1 year prior to the baseline visit;
- •Serum transaminase (ALT or AST) levels ≥2 times the upper limit of normal (ULN) during screening;
- •Creatinine clearance (Ccr) <45 mL/min (based on the Cockcroft-Gault formula) during screening;
- •Evidence of hematopoietic dysfunction during screening:
- •Hemoglobin level <9.0 g/dL or hematocrit <30%;
- •White blood cell count <3.0×10⁹/L or absolute neutrophil count (ANC) <1.2×10⁹/L;
- •Platelet count <100×10⁹/L;
- •Abnormal 12-lead ECG findings at screening or baseline that, in the investigator's judgment, may increase the safety risk of the study intervention or affect the interpretation of study results;
- •Uncontrolled hypertension with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥90 mmHg at screening/baseline;
- •Body mass index (BMI) >30 kg/m² during screening;
- •Contraindications to MRI, including but not limited to the presence of cardiac pacemakers, stents, artificial heart valves, etc.;
- •Subjects with a current psychiatric disorder such as anxiety or depression, or a history of such disorders, and who are deemed by the investigator to be unsuitable for participation in the study;
- •Subjects with a history of malignancy (except for adequately treated or excised non-metastatic basal cell or squamous cell carcinoma of the skin);
- •Pregnant or breastfeeding women, women planning to become pregnant during the study, and men planning to donate sperm during the study;
- •Use of high-dose corticosteroids (i.e., intravenous or intramuscular corticosteroids or oral prednisone equivalent >10 mg/day) or unstable doses (regardless of treatment for rheumatoid arthritis or other conditions) within 28 days prior to the baseline visit;
- •Subjects with a history of hypersensitivity to any component of the study intervention or similar compounds;
- •Participation in another interventional clinical study within 4 weeks prior to the baseline visit or within 5 half-lives of the last dose of the investigational drug at baseline;
- •History of alcohol or drug abuse within 6 months prior to the start of study intervention treatment, deemed by the investigator to hinder study participation;
- •Receipt of any live virus vaccination within 8 weeks prior to the baseline visit;
- •Subjects classified as legally disabled according to the April 2008 version of the "Law of the People's Republic of China on the Protection of Persons with Disabilities";
- •Subjects with potential health, mental, or social conditions that, in the investigator's judgment, may prevent or hinder compliance with the study protocol;
- •Peripheral or central nervous system disorders that, in the investigator's judgment, may interfere with the assessment of knee pain and function, such as fibromyalgia, significant low back pain, hip pain, sciatica, lumbar disc herniation, etc.;
- •Any other condition that is deemed by the investigator to be unsuitable for participation in the study.
研究组 & 干预措施
hiSCs treatment
Experimental
hiSCs，human induced Sertoli-like cells
干预措施: hiSCs (Biological)
结局指标
主要结局
TEAEs and SAEs
时间窗: Within 24 weeks after the injection of hiSCs
The incidence of TEAEs and SAEs related to the study intervention
WOMAC
时间窗: At 24 weeks after the injection of hiSCs
The change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score (range: 0-240 cm; including pain, stiffness, and physical function subscales) for the target knee, as assessed by the subject, with higher scores indicating greater symptom severity and worse physical function
GSUS
时间窗: At 24 weeks after the injection of hiSCs
The change from baseline in Gray-scale ultrasound (GSUS) (range: 0-12; including suprapatellar, medial, lateral, and posterior planes) for the target knee, as assessed by musculoskeletal ultrasound, with higher scores indicating more severe synovitis
PDUS
时间窗: At 24 weeks after the injection of hiSCs
The change from baseline in Power Doppler Ultrasound Synovitis (PDUS) score (range: 0-15; including suprapatellar, infrapatellar, medial, lateral, and posterior compartments) for the target knee, as assessed by power Doppler ultrasound, with higher scores indicating more severe synovitis
次要结局
- TJC(At Weeks 2, 4, 8, 12, and 24)
- SJC(At Weeks 2, 4, 8, 12, and 24)
- HAQ-DI(At Weeks 2, 4, 8, 12, and 24)
- Patient-reported pain intensity (VAS）(At Weeks 2, 4, 8, 12, and 24)
- Patient-reported global disease activity (VAS)(At Weeks 2, 4, 8, 12, and 24)
- Physician-evaluated global disease activity (VAS)(At Weeks 2, 4, 8, 12, and 24)
- SDAI score of ≤3.3(At Weeks 2, 4, 8, 12, and 24)
- SDAI(At Weeks 2, 4, 8, 12, and 24)
- CDAI score of ≤2.8(At Weeks 2, 4, 8, 12, and 24)
- CDAI(At Weeks 2, 4, 8, 12, and 24)
- Synovial thickness(At 24 weeks after the injection of hiSCs)
- Synovial blood flow(At 24 weeks after the injection of hiSCs)
- Joint effusion volume(At 24 weeks after the injection of hiSCs)
- ACR20, ACR50, ACR70(At Weeks 2, 4, 8, 12, and 24)
- Acute-phase reactant(At Weeks 2, 4, 8, 12, and 24)
- DAS28 (CRP or ESR) score of <2.6 and <3.2(At Weeks 2, 4, 8, 12, and 24)
- DAS28 (CRP or ESR)(At Weeks 2, 4, 8, 12, and 24)
- VAS(At Weeks 2, 4, 8, and 12)
- WOMAC(At Weeks 2, 4, 8, and 12)
- KOOS(At Weeks 2, 4, 8, 12, and 24)
- WORMS(At 24 weeks after the injection of hiSCs)
- MOAKS(At 24 weeks after the injection of hiSCs)
- BLOKS(At 24 weeks after the injection of hiSCs)
- GSUS(At Weeks 2, 4, 8, and 12)
- PDUS(At Weeks 2, 4, 8, and 12)
研究者
Xu huji
Professor and Chief Physician, Head of the Department of Rheumatology and Immunology, Shanghai Changzheng Hospital.
Shanghai Changzheng Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Dietary Supplements to Treat Radiation-Induced Rectal InjuryNCT06776016Sixth Affiliated Hospital, Sun Yat-sen University33
暂停
早期 1 期
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaMultiple MyleomaRefractory and Relapsed Multiple MyelomaNCT06663046Wondercel Biotech (ShenZhen)30
尚未招募
1 期
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaLeukemia, B-cellNCT06209671Beijing Immunochina Medical Science & Technology Co., Ltd.12
暂停
早期 1 期
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsB Cell LymphomaB Cell LeukemiaB Cell MalignancyNCT06662227Wondercel Biotech (ShenZhen)30
Unknown
1 期
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCCAdvanced/Metastatic Hepatocellular CarcinomaNCT04665362Liang Peng10